CHRS.NASDAQCoherus Biosciences, INC
DEF 14A: Coherus BioSciences Seeks Stockholder Approval for Amended Equity Incentive Plan at 2024 Annual Meeting
Sentiment:
Proxy Statement
Coherus BioSciences is asking stockholders to approve an amended and restated 2014 Equity Incentive Award Plan at the upcoming annual meeting on May 29, 2024, including an increase in the share reserve and elimination of the evergreen provision.
Summary
- Coherus BioSciences is holding its 2024 Annual Meeting of Stockholders virtually on May 29, 2024.
- Stockholders will vote on several proposals, including the election of three Class I directors, ratification of Ernst & Young LLP as the independent accounting firm, an advisory vote on executive compensation, and approval of the amended and restated 2014 Equity Incentive Award Plan.
- The key proposed changes to the 2014 Equity Incentive Award Plan include increasing the share reserve by 7,000,000 shares, eliminating the evergreen provision, and adding a minimum vesting provision.
- The company's board recommends voting FOR all director nominees, FOR the ratification of Ernst & Young LLP, FOR the advisory resolution on executive compensation, and FOR the approval of the amended equity incentive plan.
- The company's equity burn rate has been 5.7%, 5.7% and 5.8% in 2021, 2022 and 2023, respectively.
- If the Restated Plan is approved, the company expects its overhang rate attributable to the Restated Plan at the end of 2024 will be approximately 26%.
Sentiment
Score: 7
Explanation: The document is primarily informational and procedural, with a neutral to slightly positive sentiment due to the board's recommendations and the aim to align employee and shareholder interests.
Positives
- The amended equity incentive plan aims to align the interests of directors, employees, and consultants with those of stockholders.
- The plan includes governance best practices such as no repricing of awards and limitations on dividend payments on unvested awards.
- The company's board recommends voting FOR the election of its director nominees, FOR the ratification of the appointment of Ernst & Young LLP, FOR a non-binding, advisory resolution to approve the compensation of our named executive officers; and FOR the approval of the amendment and restatement of the 2014 Plan.
Risks
- Failure to approve the amended equity incentive plan could hinder the company's ability to attract and retain talent.
- Forward-looking statements regarding the expected overhang rate are subject to risks and uncertainties, and actual results may differ materially.
Future Outlook
The company expects the share authorization under the Restated Plan to provide enough shares for awards for approximately one year, assuming consistent grant practices and historical usage.
Industry Context
The document reflects standard corporate governance practices for publicly traded companies, particularly in the biotechnology industry, including equity compensation plans to attract and retain talent.
Comparison to Industry Standards
- The peer group used for compensation benchmarking includes companies like Acadia Pharmaceuticals, Collegium Pharmaceuticals, and Heron Therapeutics, indicating a focus on commercial-stage biopharmaceutical companies.
- The equity burn rate of 5.7% is a key metric used to assess the rate at which a company is using its equity to compensate employees, which is comparable to industry standards.
- The overhang rate of 26% is another important metric that reflects the potential dilution to existing shareholders from outstanding equity awards, which is comparable to industry standards.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Interim Chief Financial Officer | McDavid Stilwell | Bryan McMichael | December 8, 2023 | McDavid Stilwell ceased serving as our Chief Financial Officer as of December 8, 2023 and resigned his employment with us effective December 31, 2023. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Equity Incentive Plan | Increase in share reserve, elimination of evergreen provision, minimum vesting provision, and other changes to reflect compensation and governance best practices. | Upon Stockholder Approval | Aims to align employee and shareholder interests, attract and retain talent, and improve corporate governance. |
| Director Compensation Policy Changes | Changes to the Director Compensation Policy including an increase in the lead independent director's cash retainer, an increase in the chairperson of the Compensation Committee's cash compensation, and an increase in the annual grant of options to non-employee directors. | April 2024 | Aims to attract and retain qualified directors. |
Stakeholder Impact
- Shareholders: Potential dilution from increased share reserve, but also potential for increased company value through better alignment of incentives.
- Employees: Opportunity for equity-based compensation and alignment with company goals.
- Directors: Changes in compensation structure.
Next Steps
- Stockholder vote on the proposals at the 2024 Annual Meeting.
- Implementation of the amended equity incentive plan if approved by stockholders.
Key Dates
| Date | Description |
|---|---|
| 2010 | Reference to the 2010 Equity Incentive Plan. |
| 2014 | Reference to the 2014 Equity Incentive Award Plan. |
| December 31, 2023 | End of fiscal year for financial reporting. |
| April 9, 2024 | Record date for the 2024 Annual Meeting. |
| April 11, 2024 | Board of Directors approved the Restated Plan, subject to stockholder approval. |
| April 15, 2024 | Date of the proxy statement. |
| April 18, 2024 | Approximate date of mailing proxy materials to stockholders. |
| May 29, 2024 | Date of the 2024 Annual Meeting of Stockholders. |
| December 16, 2024 | Deadline for stockholder proposals to be included in the proxy materials for the 2025 annual meeting. |
| January 29, 2025 | Start date for providing written notice to the Company's Corporate Secretary for submitting a proposal before the stockholders or nominating a director at the 2025 annual meeting of the Company's stockholders. |
| February 28, 2025 | End date for providing written notice to the Company's Corporate Secretary for submitting a proposal before the stockholders or nominating a director at the 2025 annual meeting of the Company's stockholders. |
| March 30, 2025 | Deadline for shareholders who intend to solicit proxies in support of director nominees other than the Company's nominees to provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act. |
| May 29, 2025 | Anniversary of the 2024 annual meeting of the Company's stockholders. |
Keywords
equity incentive plan, annual meeting, stockholders, executive compensation, directors, Coherus BioSciences, awards, shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.